Eva Cabrera San Millan

Dr. Eva Cabrera San Millan

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2025 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
CCClara Coll-Satue
Clara Coll-Satue
EMEva Cabrera San Millan
Eva Cabrera San Millan
MJMichelle Maria Theresia Jansman
Michelle Maria Theresia Jansman
LALisa Arnholdt
Lisa Arnholdt
Leticia Hosta-RigauLeticia Hosta-Rigau
Leticia Hosta-Rigau
Hemoglobin-based oxygen carriers (HBOCs) offer a promising alternative to conventional blood transfusions in emergency scenarios. However, achieving optimal stability, functionality, and biocompatibility in HBOCs remains a significant challenge. In this study, we employed a HBOC formulation consisting of hemoglobin (Hb) encapsulated within zeolitic imidazolate framework-8 (ZIF-8) nanoparticles (NPs). These NPs were subsequently coated with metal phenolic networks (MPNs) and polyethylene glycol (PEG) to impart antioxidant properties and enhance their stability and biocompatibility. Hb-loaded ZIF-8 NPs were synthesized using a rapid, environmentally friendly protocol and exhibited desirable properties, including an average size of approximately 150 nm, a negative surface charge (zeta potential of −14 mV), high encapsulation efficiency (approximately 65%), and substantial drug loading capacity (around 70%). The MPN coating significantly enhanced stability across various buffers and cell media and endowed the NPs with antioxidant properties. Meanwhile, the PEG layer conferred stealth properties, potentially extending circulation times in vivo. Furthermore, the NPs showed excellent biocompatibility in terms of cell viability and hemolysis rate studies. They also efficiently bound and released oxygen across multiple cycles, demonstrating preserved functionality. These attributes highlight the potential of our novel HBOC as an effective oxygen delivery system and position our formulation as a promising candidate for clinical application in critical care, providing a strategic alternative to traditional blood transfusions.

26 March 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
GMGiorgia Maroni
Giorgia Maroni
IKIndira Krishnan
Indira Krishnan
RARoberta Alfieri
Roberta Alfieri
VMValerie A. Maymi
Valerie A. Maymi
NPNicole Pandell
Nicole Pandell
Elena LevantiniElena Levantini
Elena Levantini
Lung cancer is the leading cause of cancer deaths. Lethal pulmonary adenocarcinomas (ADC) present with frequent mutations in the EGFR. Genetically engineered murine models of lung cancer expedited comprehension of the molecular mechanisms driving tumorigenesis and drug response. Here, we systematically analyzed the evolution of tumor heterogeneity in the context of dynamic interactions occurring with the intermingled tumor microenvironment (TME) by high-resolution transcriptomics. Our effort identified vulnerable tumor-specific epithelial cells, as well as their cross-talk with niche components (endothelial cells, fibroblasts, and tumor-infiltrating immune cells), whose symbiotic interface shapes tumor aggressiveness and is almost completely abolished by treatment with Unesbulin, a tubulin binding agent that reduces B cell–specific Moloney murine leukemia virus integration site 1 (BMI-1) activity. Simultaneous magnetic resonance imaging (MRI) analysis demonstrated decreased tumor growth, setting the stage for future investigations into the potential of novel therapeutic strategies for EGFR-mutant ADCs. Significance: Targeting the TME is an attractive strategy for treatment of solid tumors. Here we revealed how EGFR-mutant landscapes are affected at the single-cell resolution level during Unesbulin treatment. This novel drug, by targeting cancer cells and their interactions with crucial TME components, could be envisioned for future therapeutic advancements.

26 March 2024
Verified
Other
Open access
GMGiorgia Maroni
Giorgia Maroni
IKIndira Krishnan
Indira Krishnan
RARoberta Alfieri
Roberta Alfieri
VMValerie A. Maymi
Valerie A. Maymi
NPNicole Pandell
Nicole Pandell
Elena LevantiniElena Levantini
Elena Levantini
Supplementary Table 7. Size of each identified transcriptional cluster as percentage of all profiled cells.

26 March 2024
Verified
Other
Open access
GMGiorgia Maroni
Giorgia Maroni
IKIndira Krishnan
Indira Krishnan
RARoberta Alfieri
Roberta Alfieri
VMValerie A. Maymi
Valerie A. Maymi
NPNicole Pandell
Nicole Pandell
Elena LevantiniElena Levantini
Elena Levantini
ScRNA-seq of healthy and tumor-bearing lungs highlights presence of pulmonary milieu clusters. A, t-SNE plot of the 41 clusters identified in healthy lungs (n = 3, left), and Vehicle- (n = 10, middle), or Unesbulin-treated tumors (n = 3, right), at 30 days. Each point represents one cell. Each color represents a defined transcriptional cluster as shown in the corresponding legends. B, t-SNE plot in which transcriptional clusters have been annotated as epithelial, immune, endothelial, or fibroblast subpopulations. C, Cluster distribution superimposed to clusters annotation within epithelial, immune, endothelial cells, and fibroblasts in healthy lungs (left), and Vehicle- (middle), or Unesbulin-treated tumors (right).

10 April 2025
Verified
Other
Open access
GMGiorgia Maroni
Giorgia Maroni
IKIndira Krishnan
Indira Krishnan
RARoberta Alfieri
Roberta Alfieri
VMValerie A. Maymi
Valerie A. Maymi
NPNicole Pandell
Nicole Pandell
Elena LevantiniElena Levantini
Elena Levantini
Supplementary Table 14. Size of each identified transcriptional cluster as percentage of all profiled fibroblasts.

26 March 2024
Verified
Other
Open access
GMGiorgia Maroni
Giorgia Maroni
IKIndira Krishnan
Indira Krishnan
RARoberta Alfieri
Roberta Alfieri
VMValerie A. Maymi
Valerie A. Maymi
NPNicole Pandell
Nicole Pandell
Elena LevantiniElena Levantini
Elena Levantini
Supplementary Table 14. Size of each identified transcriptional cluster as percentage of all profiled fibroblasts.